We use cookies on accura.dk

accura.dk uses cookies to improve the user-friendliness and functionality. By using our website, you consent to our use of cookies. Read more about cookies at accura.dk. Enjoy.

Read more about our cookie policy and instructions to delete cookies


DSM acquires Danish biotech company in billion-kroner transaction

Case info

The Dutch enzyme and ingredients group DSM has acquired the Danish biotech company Glycom in a transaction valuing Glycom at EUR 765 million.

Glycom was formed in 2005 by glucose research scientists and chemists from the Technical University of Denmark (DTU). The company is the global market leader within the development and manufacture of HMOs. HMOs are small fibres that exist in mother's milk and that help ensure a healthy intestinal flora in children and adults. The fibres are believed to play key roles in many of the health-promoting effects of mother's milk. In 2016, Glycom was the first company in the world to have an HMO approved for use in infant formula.

Glycom is based in Hørsholm, Denmark, and, today, has research scientists and developers from 15 different countries.

DSM is a world-leading group within the development and manufacture of enzymes and ingredients. The company has more than 23,000 employees.

Thomas Weincke, Mads Ilum, Morten Bruus, Louise Hilligsøe Nørgaard and Christoffer Ege Andersen advised DSM in connection with the transaction.


Thomas Weincke
Thomas Weincke

Partner, Attorney-at-Law

Mobile: +45 3078 6678

Accura's recent cases

We advise in connection with the largest and most complex transactions on the market.

Read a selection of our cases here.

Accura's recent cases

Accura's M&A Team

Accura's M&A Team